Numerically higher CD4+ and CD8+ T-cells and significantly higher CD20+ B-cells in the tumor immune microenvironment at baseline support the local immunostimulatory effect of the treatment and were associated with improved clinical outcomes to trametinib and pembrolizumab (Fig. 2A, B, C, D). Here, CD8A is linked to neoplasm.